SSI Strategy and NDA Group merge to become a comprehensive life sciences consultancy

SSI Strategy a leading Life Sciences consultancy, today announced that it has entered into a definitive agreement to
acquire NDA Group AB, a leading regulatory affairs and drug development consultancy.

This strategic combination will create a premier consultancy, specializing in guiding drugdevelopment companies from concept to commercialization, helping optimize thedevelopment process and maximize the therapeutic value of complex and novel treatments.

The merger marks an exciting milestone following years of successful collaboration across numerous clients, resulting in the launch of the most innovative therapies available in the world today.

Financial terms of the transaction were not disclosed.

“NDA Group is regarded as the premier regulatory consultancy for Life Sciences companies across the U.S. and Europe, and we’re delighted to build upon our longstanding partnership with this combination,” said Doug Locke, Chief Executive Officer of SSI Strategy. “This transaction brings together two highly regarded consultancies to create an integrated, end-to-end provider of drug development and regulatory consulting services. Combined, we will provide our common client base with best-in-class clinical development and regulatory expertise. Over years of collaboration between our businesses, we have proven our ability to execute together and are confident the success we have shared on prior partnerships will translate into more value for our clients from day one.”

Johan Strömquist, CEO of NDA Group, commented, “SSI’s unparalleled combination of business acumen and medical expertise has formed a unique space in the Life Sciences market. We are excited to join forces with them to expand upon this platform together. While NDA Group has been a world leading regulatory development consultancy for the past 25 years, there are still challenges that biotechs face that we have not been able to fully address. Together with SSI, we can not only optimize the regulatory path, but now also partner with our clients to execute the entire development program. For our clients, this will mean reduced risk, reduced costs, increased success rates and faster time to market. For the patient, this means higher quality treatments without unnecessary delay.”

Avi Uttamchandani, Principal at Amulet added, “Together, SSI and NDA will create a leading Life Sciences and drug development consultancy positioned to support both emerging and established biotechnology companies at every stage of the drug development and approval process. This combination will significantly enhance SSI’s regulatory support services and grow its industry leading team of experts while positioning the Company to grow its geographic footprint and expand its presence serving clients across the U.S. and Europe.”

Following the close of the transaction, NDA will operate as a strategic business unit (SBU) under SSI. SSI Strategy President Adam Schwartz will continue to lead SSI’s operations while the NDA management team will continue leading the NDA SBU under the guidance of President Johan Strömquist.